OncoResponse Inc., a privately held immuno-oncology company, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to the discovery of cancer therapeutics.

OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of antibody-derived therapeutics for the treatment of cancer, thereby extending the benefit of immunotherapy to a greater number of patients.

OncoResponse has licensed the I-STAR™ platform, developed and clinically validated by Theraclone Sciences, to interrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy. These Elite Responders provide the key to unlocking the immune response to cancer, as their adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses.

OncoResponse has formed a strategic alliance with MDACC who, along with Rice University, made an equity investment in the company. MDACC is one of the world's largest cancer centers and a leader in immunotherapy research, clinical development and patient care.

OncoResponse has assembled an expert management team with a successful track record of drug discovery and development. The company is guided by an experienced board of directors, a knowledgeable scientific and clinical advisory panel and strong investors.